Cargando…

Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus

OBJECTIVE: In SLE, smoking increases the burden of cutaneous disease and organ damage, and leads to premature mortality. However, the effect of smoking on disease manifestations and cytokine levels of patients with SLE is unclear. This study compared characteristics of patients with SLE across smoki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raymond, Warren David, Hamdorf, Matthew, Furfaro, Michael, Eilertsen, Gro Ostli, Nossent, Johannes Cornelis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Biomarker Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562512/ https://www.ncbi.nlm.nih.gov/pubmed/34725185 http://dx.doi.org/10.1136/lupus-2021-000537

Ejemplares similares

The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
por: Raymond, Warren David, et al.
Publicado: (2019)

Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation
por: Nossent, Johannes C, et al.
Publicado: (2016)

Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus
por: Raymond, Warren, et al.
Publicado: (2018)

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
por: Northcott, Melissa, et al.
Publicado: (2022)

Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus
por: Nielsen, Christoffer T, et al.
Publicado: (2014)

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus
por: Petri, Michelle A, et al.
Publicado: (2020)

Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational study
por: Compagno, Michele, et al.
Publicado: (2014)

BAFF polymorphisms and serum levels of BAFF in Tunisian systemic lupus erythematosus patients
por: Laamiri, Nacira, et al.
Publicado: (2012)

Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2018)

Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus
por: Mackay, Meggan, et al.
Publicado: (2015)

Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children
por: Brunner, Hermine I, et al.
Publicado: (2014)

Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection
por: Mackay, Meggan, et al.
Publicado: (2016)

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
por: Idborg, Helena, et al.
Publicado: (2018)

Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus
por: Sadras, Vignesh, et al.
Publicado: (2020)

Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus
por: Cornwell, MacIntosh Grant, et al.
Publicado: (2021)

Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
por: Ruacho, Guillermo, et al.
Publicado: (2022)

Elevation of serum anti–glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus
por: Matsueda, Yu, et al.
Publicado: (2018)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Serum interferon-alpha predicts in-hospital mortality in patients hospitalised with acute severe lupus
por: Yerram, Keerthi Vardhan, et al.
Publicado: (2023)

Hospitalisation for systemic lupus erythematosus associates with an increased risk of mortality in Australian patients from 1980 to 2014: a longitudinal, population-level, data linkage, cohort study
por: Raymond, Warren David, et al.
Publicado: (2021)

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products
por: Wallace, Daniel J, et al.
Publicado: (2016)

Differential expression of antibodies to NMDA receptor in anti-NMDA receptor encephalitis and in neuropsychiatric systemic lupus erythematosus
por: Hirohata, Shunsei, et al.
Publicado: (2019)

RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin
por: Merola, Joseph F, et al.
Publicado: (2021)

Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus
por: Fasano, Serena, et al.
Publicado: (2022)

Expression of BAFF and BR3 in patients with systemic lupus erythematosus
por: Duan, J.H., et al.
Publicado: (2016)

Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up
por: Schoindre, Yoland, et al.
Publicado: (2014)

Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density
por: Shevchuk, Sergii, et al.
Publicado: (2023)

Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies
por: Brunekreef, Tammo, et al.
Publicado: (2021)

Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus
por: Anderson, Erik W, et al.
Publicado: (2021)

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus
por: Alexander, Roberta Vezza, et al.
Publicado: (2021)

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements
por: Putterman, Chaim, et al.
Publicado: (2014)

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016)

BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year
por: Zollars, Eric, et al.
Publicado: (2015)

B cells, BAFF/zTNF4, TACI, and systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2001)

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)
por: Conklin, John, et al.
Publicado: (2022)

Mesenchymal stem cells and T cells in the formation of Tertiary Lymphoid Structures in Lupus Nephritis
por: Dorraji, S. Esmaeil, et al.
Publicado: (2018)

Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms
por: George-Chandy, Annie, et al.
Publicado: (2008)

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus
por: Shin, Woori, et al.
Publicado: (2018)

Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial
por: McDonald, Stephen, et al.
Publicado: (2022)

Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis
por: Marín-Rosales, Miguel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3gbg4oa32e9arcv2a6ug5fbmct